Purinergic Receptor (Purinoceptor) Antagonists - Pipeline Insight, 2024

This “Purinergic Receptor (Purinoceptor) Antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Purinergic Receptor (Purinoceptor) Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Purinergic Receptor (Purinoceptor) Antagonists Understanding

Purinergic Receptor (Purinoceptor) Antagonists: Overview

Membrane receptors that are activated by the purine nucleoside adenosine (adenosine receptors) or by purine or pyrimidine nucleotides (P2Y and P2X receptors) transduce extracellular signals to the cytosol. They play important roles in physiology and disease. The G protein-coupled adenosine receptors comprise four subtypes: A1, A2A, A2B, and A3. The G-protein-coupled P2Y receptors are subdivided into eight subtypes: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14, while the P2X receptors represent ATP-gated homomeric or heteromeric ion channels consisting of three subunits; the most important subunits are P2X1, P2X2, P2X3, P2X4, and P2X7. Purinergic receptors play important roles in central nervous system (CNS). These receptors are involved in cellular neuroinflammatory responses that regulate functions of neurons, microglial and astrocytes. Based on their endogenous ligands, purinergic receptors are classified into P1 or adenosine, P2X and P2Y receptors. During brain injury or under pathological conditions, rapid diffusion of extracellular adenosine triphosphate (ATP) or uridine triphosphate (UTP) from the damaged cells, promote microglial activation that result in the changes in expression of several of these receptors in the brain.

Purinergic Receptor (Purinoceptor) Antagonists - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Purinergic Receptor (Purinoceptor) Antagonists pipeline landscape is provided which includes the disease overview and Purinergic Receptor (Purinoceptor) Antagonists treatment guidelines. The assessment part of the report embraces, in depth Purinergic Receptor (Purinoceptor) Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Purinergic Receptor (Purinoceptor) Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Purinergic Receptor (Purinoceptor) Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Purinergic Receptor (Purinoceptor) Antagonists.

Purinergic Receptor (Purinoceptor) Antagonists Emerging Drugs Chapters

This segment of the Purinergic Receptor (Purinoceptor) Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Purinergic Receptor (Purinoceptor) Antagonists Emerging Drugs

Gefapixant: Merck & Co Gefapixant, an investigational, orally administered, selective Purinergic P2X3 receptor antagonist, for the treatment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) in adults. In March 2021, Merck known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) forgefapixant.

Selatogrel: Idorsia Pharmaceuticals Selatogrel acts as P2Y12 receptor antagonist, it is administered subcutaneously. It is being developed by Antares Pharma in partnership with Idorsia Pharmaceuticals for the treatment of myocardial infarction using Antare’s Quickshot auto-injector. It is currently in Phase III stage of development.

Purinergic Receptor (Purinoceptor) Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Purinergic Receptor (Purinoceptor) Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Purinergic Receptor (Purinoceptor) Antagonists

There are approx. 40+ key companies which are developing the therapies for Purinergic Receptor (Purinoceptor) Antagonists. The companies which have their Purinergic Receptor (Purinoceptor) Antagonists drug candidates in the most advanced stage, i.e. Pre-registration include, Merck & Co.

Phases

This report covers around 40+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Purinergic Receptor (Purinoceptor) Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Purinergic Receptor (Purinoceptor) Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Purinergic Receptor (Purinoceptor) Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Purinergic Receptor (Purinoceptor) Antagonists drugs.

Purinergic Receptor (Purinoceptor) Antagonists Report Insights

• Purinergic Receptor (Purinoceptor) Antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Purinergic Receptor (Purinoceptor) Antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Purinergic Receptor (Purinoceptor) Antagonists drugs?
• How many Purinergic Receptor (Purinoceptor) Antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Purinergic Receptor (Purinoceptor) Antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Purinergic Receptor (Purinoceptor) Antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Purinergic Receptor (Purinoceptor) Antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Incyte Corporation
• Arcus Biosciences
• Corvus Pharmaceuticals
• Idorsia Pharmaceuticals
• Tarus Therapeutics
• Dizal Pharmaceutical
• Corvus Pharmaceuticals

Key Products

• INCB-106385
• Etrumadenant
• Ciforadenant
• Selatogrel
• TT-4
• TT-10
• DZD-2269
• Ciforadenant

This product will be delivered within 2-4 business days.